Perrigo (NYSE:PRGO) Stock Rating Upgraded by Wall Street Zen

Perrigo (NYSE:PRGO) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

PRGO has been the subject of several other research reports. Zacks Research upgraded Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Weiss Ratings upgraded Perrigo from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Perrigo has a consensus rating of “Hold” and a consensus price target of $19.33.

Perrigo Price Performance

Shares of NYSE:PRGO opened at $12.83 on Friday. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -1.03, a P/E/G ratio of 1.46 and a beta of 0.51. The firm has a fifty day moving average price of $10.62 and a 200 day moving average price of $11.51. Perrigo has a fifty-two week low of $9.23 and a fifty-two week high of $24.60. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.32 and a current ratio of 2.32.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.11. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the firm posted ($0.06) EPS. Perrigo’s revenue for the quarter was down 3.1% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, sell-side analysts expect that Perrigo will post 2.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. lifted its position in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after purchasing an additional 786 shares during the period. Kestra Investment Management LLC raised its stake in Perrigo by 57.1% in the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after buying an additional 642 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Perrigo by 116.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock worth $26,000 after buying an additional 1,014 shares in the last quarter. UMB Bank n.a. lifted its holdings in Perrigo by 161.5% during the fourth quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after buying an additional 1,213 shares during the period. Finally, Meeder Asset Management Inc. bought a new stake in Perrigo during the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.